Frankfurt - Delayed Quote EUR

MediPharm Labs Corp. (MLZ.F)

0.0398

-0.0048

(-10.76%)

At close: May 30 at 3:45:47 PM GMT+2

MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital

Demands Management’s Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws URGES SHAREHOLDERS TO VOTE THE GOLD PROXY CARD "FOR" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES AND DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”), which together with its affiliates and associates collectively is one of the largest shar

GlobeNewswire yesterday

MEDIF
Apollo Capital alleges securities fraud at Medipharm Labs

Apollo Technology Capital, which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs (MEDIF), owning approximately 3% of the Company’s common stock, issued anurgent warning to shareholders, regulators, and the investing public concerning allegations of alleged securities act disclosure violations committed by MediPharm Labs’ Board of Directors and management team. Apollo said, “Apollo Capital has received alarming reports from multiple hi

TipRanks 2 days ago

MEDIF
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo Technology Capital Corporation (“Apollo”) on May 29, 2025 making baseless allegations of malfeasance against the Company. These patently false allegations have been intentionally or recklessly fabricated as part of the

GlobeNewswire 2 days ago

MEDIF
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital

Multiple Highly Credible Sources Reveal Disturbing Evidence of Alleged Systemic Violations of Securities Laws at MediPharm Labs; Immediate Regulatory Action Demanded Apollo Capital’s Six Director Nominees Are Committed to Restoring Transparency and Value to MediPharm’s Shareholders URGES SHAREHOLDERS TO VOTE THE GOLD PROXY CARD "FOR" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES AND DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporatio

GlobeNewswire 3 days ago

MEDIF
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter to Shareholders from the Company’s Board of Directors (the “Letter”). The Letter is a response to the amended and restated dissident proxy circular filed by Apollo on May 20, 2025, and in particular Apollo’s plan for the Company. The full text of the Letter to Shareholders follows. MESSAGE FROM THE M

GlobeNewswire 4 days ago

MEDIF
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma

Opioid-Pusher Pidduck, Chairman Chris Taves and the Current MediPharm Board Have Presided Over $1 Billion in Shareholder Value Destruction while funneling $5,587,059 of the Shareholders’ Money Directly into Pidduck’s Pocket Apollo Capital’s Six Director Nominees Are Committed to Restoring Transparency and Value to MediPharm’s Shareholders URGES SHAREHOLDERS TO DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD AND VOTE THE GOLD PROXY CARD "FOR" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES TORONTO, May 27, 202

GlobeNewswire 5 days ago

MEDIF
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement

TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those t

GlobeNewswire 6 days ago

MEDIF
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.

TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “Dissident Nominees”) nominated by Apollo Technology Capital Corporation (“Apollo”) to stand for election at MediPharm’s Annual and Special Meeting of Shareholders on June 16, 2025. All dollar figures in this news release ar

GlobeNewswire 9 days ago

MEDIF
Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting

MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair Failure to Appoint an Independent Chair to Oversee the Election of Directors at the Annual Meeting Prevents Shareholders from Exercising their Legal Right to Hold the Current Board Accountable for their Epic Failures Board Made No Attempt to Engage with Apollo Capital; Instead Resorted to Continued Campaign of Misdirection and Character Assassination Aimed to Undermine Shareholders Demanding Change S

GlobeNewswire 9 days ago

MEDIF
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “Purchase Agreement”) for the sale of MediPharm’s facility in Hope, BC, (“Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). With these conditio

GlobeNewswire 10 days ago

MEDIF

ROMJF
MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings

TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its shareholders to publicly available information about Regan McGee, the controlling shareholder, director, Chairman and CEO of Apollo Technology Capital Corporation (“Apollo”), a dissident MediPharm shareholder. Apollo filed an amended and restated dissident proxy circular on May 20, 2025 (the “Dissident C

GlobeNewswire 10 days ago

MEDIF
COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of Transparency Under Current Leadership

Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today announced that it has filed an amended and restated information circular (the "Circular") in connection with its intention to nominate six highly qualified director can

PR Newswire 12 days ago

MEDIF
Apollo Capital Warns MediPharm Shareholders of Continued Value Destruction and Insolvency Risk Following Disastrous Q1 Financial Results

Apollo Technology Capital Corporation ("Apollo Capital"), one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), owning approximately 3.0% of the Company's common stock, today commented on MediPharm's first quarter 2025 financial results, reported earlier this week, which reinforce the urgent need for board-level change to reverse the Company's rapidly deteriorating financial position.

PR Newswire 16 days ago

MEDIF
TSX Penny Stocks To Watch In May 2025

As trade tensions ease with new agreements and the Federal Reserve maintains its interest rate, the Canadian market is experiencing a period of cautious optimism. This backdrop creates a unique opportunity for investors to explore smaller or newer companies that might be overlooked in more stable times. While "penny stocks" may seem like an outdated term, they continue to represent potential value, especially when these companies are built on solid financial foundations and demonstrate...

Simply Wall St. 16 days ago

PLNH

CANOF

MEDIF
MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees

MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with additional information about the six nominees for its board of directors (the "Dissident Nominees") submitted by Apollo Technology Capital Corporation ("Apollo").

CNW Group 17 days ago

MEDIF
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today posed several critical questions that shareholders should ask MediPharm management on this morning's conference call following its first quarter 2025 earnings report. C

PR Newswire 18 days ago

MEDIF

CHEK
MediPharm Labs Announces Strong Q1 2025 Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, announces financial results for the three months ended March 31, 2025 ("Q1 2025").

PR Newswire 18 days ago

MEDIF
MediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders

MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular ("MIC" or the "Circular") and proxy materials (the "Meeting Materials") for its upcoming Annual and Special Meeting of Shareholders, scheduled for June 16, 2025. The Meeting Materials will be sent to shareholders in the coming days, and are available on the SEDAR+ website at www.sedarplus.ca.

PR Newswire 19 days ago

MEDIF
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector MediPharm pushed back against Apollo’s boardroom challenge Organigram was named “Exporter of the Year” for cannabis innovation and global reach Green Thumb posted solid Q1 2025 results, as the company focuses on brand expansion and market growth Key Takeaways; Psychedelic Sector Bright Minds won Wall Street confidence with $80 price target […]

Market Exclusive 20 days ago

MEDIF

MIRA

DRUG
MediPharm Labs Sets Date to Report First Quarter 2025 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2025, before markets open on Wednesday, May 14, 2025.

PR Newswire 23 days ago

MEDIF

Performance Overview

Return	MLZ.F	S&P/TSX Composite index (^GSPTSE)
YTD	--	+6.31%
1-Year	-21.65%	+18.59%
3-Year	-26.30%	+25.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MediPharm Labs Corp. (MLZ.F)

MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital

Apollo Capital alleges securities fraud at Medipharm Labs

MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder

Alleged Securities Fraud at MediPharm Labs Says Apollo Capital

MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan

Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma

MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement

MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.

Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting

MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June

MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings

COMPLETE Board Change is Urgently Needed at MediPharm Labs! Apollo Technology Capital Corporation Files Amended and Restated Proxy Circular Detailing Prolonged Underperformance, Strategic Failures, Excessive Executive Compensation, and Troubling Lack of Transparency Under Current Leadership

Apollo Capital Warns MediPharm Shareholders of Continued Value Destruction and Insolvency Risk Following Disastrous Q1 Financial Results

TSX Penny Stocks To Watch In May 2025

MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees

Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

MediPharm Labs Announces Strong Q1 2025 Results

MediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

MediPharm Labs Sets Date to Report First Quarter 2025 Financial Results

Performance Overview